PubMed Health⌕ Search

Biomedical subjects

T Longley

Publications and source records attributed to T Longley.

2 recordsLinked to original sources

A sensitive lacZ-based expression vector for analyzing transcriptional control elements in eukaryotic cells.

We have developed a eukaryotic expression vector that provides a rapid and sensitive measure of transcriptional activity modulated by general and tissue-specific regulatory motifs. The lacZ structural gene has been linked to the minimal promoter of the human liver/bone/kidney alkaline phosphatase gene. In addition, a trimerized cassette of the SV40 polyadenylation region has been placed 5' of this promoter to reduce plasmid-initiated transcripts extending through the lacZ gene that would contribute to background beta-galactosidase (beta-Gal) activity. By combining the weak promoter and the poly(A) cassette, only a very low level of lacZ activity is detected in the absence of additional regulatory sequences. Regulatory domains can be inserted into this vector via a unique Bam HI restriction site and their activity can be rapidly monitored in situ via a colorimetric 5-bromo-4-chloro-3-indolyl-beta-D-galactoside (X-Ga) staining protocol. Also, the activity of linked regulatory domains can be measured quantitatively by assaying beta-Gal levels in cell extracts. We show that derivatives of this vector can be used to monitor the activity of general and tissue-specific control elements and can be transactivated by a single transcription factor in cotransfection experiments.

Alkaline Phosphatase↗

Determination of iron absorption using erythrocyte iron incorporation of two stable isotopes of iron (57Fe and 58Fe) in very low birthweight premature infants.

Due to limited erythropoiesis, iron needs for the premature infant during the first 2 months of life are low. With the potential for increased use of erythropoietin in the preterm infant, iron requirements may become markedly higher. The ability of the preterm infant to absorb iron, therefore, becomes crucial. Previous studies using single stable isotopes of iron without metabolic balances were unable to quantitatively determine iron absorption since the percentage of absorbed iron appearing in the erythrocyte could not be measured. The objective of the current study was to determine iron absorption using the method of erythrocyte iron incorporation of two stable isotopes of iron given by the enteral and parenteral route to very low birth weight (VLBW) infants. Results obtained were compared to iron absorption values from studies using single isotopes and metabolic balance techniques. Six VLBW premature infants (gestational age 26.8 +/- 1.7 weeks, postnatal age 3.6 +/- 1.9 weeks, birth weight 863 +/- 117 g) were studied. Iron dosages were (i.v.) 0.15 mg/kg (57FeSO4) and (enteral) 1.5 mg/kg (58FeSO4). Erythrocyte isotope ratios, 57Fe/54Fe and 58Fe/54Fe, were determined by inductively coupled plasma mass spectrometry (ICP/MS) from single blood samples (100 microliters) collected before and after concurrent enteral (58Fe) and parenteral (57Fe) administration of isotopes. Only 17.8% of the i.v.-infused iron dose was incorporated into hemoglobin on day 15. Using a correction factor based on the percentage of i.v. iron (57Fe) incorporated into erythrocytes, the corrected incorporation of 58Fe was calculated to be 26.3 +/- 13.0% of the enteral dose of 58FeSO4.

Absorption↗